Official Title: “Non-Interventional Study on Uncontrolled Hypertensive Patients for Evaluating Efficacy of Candesartan Cilexetil as Monotherapy or Add-on Therapy.”

The purpose of this study is to observe treatment with candesartan cilexetil 16mg for 8 weeks, in uncontrolled hypertensive patients, in improvement of achieving of treatment goals and impact on blood pressure level in patients with uncontrolled hypertension treated with candesartan cilexetil.

Study Type: Observational

Study Design: Prospective

Intervention(s) in this Clinical Trial

• Drug: Candesartan Cilexeotil 16mg

Inclusion Criteria:

• diagnosis of essential hypertension (mild or moderate as defined in European
• Guidelines of Hypertension, 2003), that are treated already with candesartan cilexetil 16mg o.d. within last 2 weeks or more, according to Romanian approved Atacand SPC.
• Written informed consent to allow access and use(analysis) of data collected

Exclusion Criteria:

• Patients not to be included in the programme: patients who have any contraindication to the product as detailed in Romanian approved Atacand SPC.
• Use of specific concomitant medication known to present a potential safety concern according to Romanian approved SPC

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: AstraZeneca

Overall Clinical Trial Officials and Contacts

Cristina Pentiuc Study Director AstraZeneca  

Overall Contact: AstraZeneca Romania Medical Department Clinical Study, Information +4021 317 60 41 otilia.radu@astrazeneca.com

Information obtained from ClinicalTrials.gov on July 02, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00573742

Study ID Number: NIS-ATO-HCH-2007/2

ClinicalTrials.gov Identifier: NCT00573742

Health Authority: Romainia: National Drug Agency